Bhargava, Balram

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Ella, R., Vadrevu, K. M., Jogdand, H., Prasad, S., Reddy, S., Sarangi, V., Ganneru, B., Sapkal, G., Yadav, P., Abraham, P., et al. (2021) · The Lancet Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 424

Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees

Yadav, P. D., Sapkal, G. N., Abraham, P., Ella, R., Deshpande, G., Patil, D. Y., Nyayanit, D. A., Gupta, N., Sahay, R. R., Shete, A. M., et al. (2022) · Clinical Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 251

SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021

Murhekar, M. V., Bhatnagar, T., Thangaraj, J. W. V., Saravanakumar, V., Kumar, M. S., Selvaraju, S., Rade, K., Kumar, C. P. G., Sabarinathan, R., Turuk, A., et al. (2021) · International Journal of Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 134

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model

Mohandas, S., Yadav, P. D., Shete-Aich, A., Abraham, P., Vadrevu, K. M., Sapkal, G., Mote, C., Nyayanit, D., Gupta, N., Srinivas, V. K., et al. (2021) · iScience

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 74

Neutralization Potential of Covishield Vaccinated Individuals Sera Against B.1.617.1

Yadav, P. D., Sapkal, G. N., Abraham, P., Deshpande, G., Nyayanit, D. A., Patil, D. Y., Gupta, N., Sahay, R. R., Shete, A. M., Kumar, S., et al. (2022) · Clinical Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 51